Quarterly cross-cutting synthesis of psychedelic research across major regions — the dynamics, regulatory shifts, and clinical clusters that aren't visible from country pages alone.
Looking for something specific? Ask Blossom
Regional Roundup
·2026-Q2
Asia-Pacific is entering 2026-Q2 as a region of regulatory contrast rather than convergence. Australia remains the only jurisdiction in this group with a formal, narrow prescribing route for MDMA and psilocybin, but the
Regional Roundup
·2026-Q2
Europe’s psychedelic medicine story in 2026-Q2 is best read as a regional convergence of two tracks, not a single market: tightly controlled classical psychedelics remain largely trial-bound, while esketamine and, in a f
Regional Roundup
·2026-Q2
Latin America’s psychedelic research story in 2026-Q2 is still defined by fragmentation, but the region is becoming easier to read as a set of linked regulatory and scientific patterns rather than six separate country ca
Regional Roundup
·2026-Q2
MENA remains a patchwork region for psychedelic medicine in 2026-Q2, but the cross-border story is less about broad liberalisation than about a narrow set of medical exceptions, mostly around ketamine and esketamine, alo
Regional Roundup
·2026-Q2
North America in 2026-Q2 remains the region where psychedelic medicine is advancing on multiple tracks at once, but not in a shared regulatory direction. The United States continues to anchor the world’s deepest trial an
Regional Roundup
·2026-Q2
Sub-Saharan Africa remains a sparse but increasingly legible region for psychedelic medicine in Blossom’s Q2 2026 dataset. The strongest signal is concentrated in South Africa, where Blossom tracks 6 trials and a private